Beta
Felodipine
medication Under reviewA calcium channel blocker medication used to treat hypertension.
Research summary
Clinical research on felodipine in humans is extensive and focuses almost entirely on patients with essential hypertension or cardiovascular disease rather than on healthy normotensive volunteers. Randomized controlled trials and long‑term studies demonstrate that felodipine, particularly in extended‑release formulations, effectively lowers systolic and diastolic blood pressure and can lead to regression of left ventricular hypertrophy when used for a year or longer in hypertensive patients. Dose‑finding studies in adults with uncomplicated hypertension identify a clear dose–response relationship, with typical starting doses around 5 mg per day or 5 mg twice daily in older trials. Overall, the evidence base supports felodipine as an effective and generally well‑tolerated antihypertensive agent, with common adverse effects such as peripheral edema, flushing, and headache related to its vasodilatory mechanism. In heart failure populations already treated with guideline‑directed therapy, adding felodipine produces favorable hemodynamic changes but does not translate into robust improvements in mortality or hospitalization, though it may help maintain exercise tolerance and quality of life in some patients. Importantly, studies are therapeutic and disease‑oriented; there is no evidence base supporting felodipine for enhancement of health or performance in otherwise healthy normotensive individuals.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Felodipine to your stack to report effects
Tolerability of different doses of felodipine extended-release in hypertensive adults: trial registration ISRCTN56240656
Not specified
Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.
Komajda M, Lutiger B, Madeira H, et al.
One-year study of felodipine or placebo for stage 1 isolated systolic hypertension.
Neaton JD, Grimm RH, Prineas RJ, et al.
Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.
Andersson OK, Hökfelt B, Karlberg BE, et al.
No reports yet
Be the first to report this effect and help the community.
Add Felodipine to your stack to report effects
Tolerability of different doses of felodipine extended-release in hypertensive adults: trial registration ISRCTN56240656
Not specified
One-year study of felodipine or placebo for stage 1 isolated systolic hypertension.
Neaton JD, Grimm RH, Prineas RJ, et al.
Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.
Andersson OK, Hökfelt B, Karlberg BE, et al.
No reports yet
Be the first to report this effect and help the community.
Add Felodipine to your stack to report effects
Tolerability of different doses of felodipine extended-release in hypertensive adults: trial registration ISRCTN56240656
Not specified
Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.
Andersson OK, Hökfelt B, Karlberg BE, et al.
One-year study of felodipine or placebo for stage 1 isolated systolic hypertension.
Neaton JD, Grimm RH, Prineas RJ, et al.
Reported Side Effects
No reports yet
Be the first to report this effect and help the community.
Add Felodipine to your stack to report effects
Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.
Komajda M, Lutiger B, Madeira H, et al.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Coronary artery disease or other cardiac conditions
Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.
Komajda M, Lutiger B, Madeira H, et al.
Hypertension — elevated blood pressure requiring management
One-year study of felodipine or placebo for stage 1 isolated systolic hypertension.
Neaton JD, Grimm RH, Prineas RJ, et al.
Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.
Andersson OK, Hökfelt B, Karlberg BE, et al.
Tolerability of different doses of felodipine extended-release in hypertensive adults: trial registration ISRCTN56240656
Not specified
Research (4 studies)
Tolerability of different doses of felodipine extended-release in hypertensive adults: trial registration ISRCTN56240656
Not specified
One-year study of felodipine or placebo for stage 1 isolated systolic hypertension.
Neaton JD, Grimm RH, Prineas RJ, et al.
Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.
Komajda M, Lutiger B, Madeira H, et al.
Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.
Andersson OK, Hökfelt B, Karlberg BE, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!